Join Growin Stock Community!

Chemomab therapeutics ltd.CMMB.US Overview

US StockHealthcare
(No presentation for CMMB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CMMB AI Insights

CMMB Overall Performance

CMMB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CMMB Recent Performance

-3.23%

Chemomab therapeutics ltd.

0.05%

Avg of Sector

-0.31%

S&P500

CMMB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CMMB Key Information

CMMB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CMMB Profile

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Price of CMMB

CMMB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CMMB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.64
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.02
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.64
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.02
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CMMB's latest earnings report released?

    The most recent financial report for Chemomab therapeutics ltd. (CMMB) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CMMB's short-term business performance and financial health. For the latest updates on CMMB's earnings releases, visit this page regularly.

  • How much cash does CMMB have?

    At the end of the period, Chemomab therapeutics ltd. (CMMB) held Total Cash and Cash Equivalents of 7.12M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CMMB's EPS continuing to grow?

    According to the past four quarterly reports, Chemomab therapeutics ltd. (CMMB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of CMMB?

    The latest valuation data shows Chemomab therapeutics ltd. (CMMB) has a Price-To-Earnings (PE) ratio of -1.54 and a Price/Earnings-To-Growth (PEG) ratio of 0.11. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.